English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A new series of 1,3,4-oxadiazole bearing pyrimidine-pyrazine derivatives ( 9a–j ) was developed and examined for their preliminary anticancer effects against four human cancer cell lines such as PC3 &amp;DU-145 (prostate cancer), A549 (lung cancer) and MCF-7 (breast cancer). The well-known chemotherapeutic agent as etoposide used as a positive control. The IC 50  values range of target compounds from 0.05 ± 0.007 µM to 9.44 ± 5.36 µM, whereas positive control displayed values from 1.97 ± 0.45 µM to 3.08 ± 0.135 µM, respectively. Among them, five compounds ( 9a, 9b, 9c, 9g  and  9j)  exhibited most potent activities. Predominantly, one compound  9a  showed superior activity.

Synthesis and biological evaluation of 1,3,4-oxadiazole bearing pyrimidine-pyrazine derivatives as anticancer agents